Anteris Technologies Global Corp.
HealthcareNASDAQ:AVR · NASDAQ Global Market
-$0.16 today
Vol 0.69M · Avg 1.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
101230.1%
avg 16622.3%
ROIC
-4256.3%
avg -871.6%
ROA
-409.4%
avg -174.5%
Analysis
ROE is currently the strongest return metric at 101230.1% versus its period average of 16622.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Wayne Geoffrey Paterson | Vice Chairman & Chief Executive Officer | $1.67M | — | 59 | $666,667.00 | 1.81% |
David Denis | President & Director | $981,905.00 | — | 57 | $35,162.00 | 0.10% |
Matthew McDonnell | Chief Financial Officer | $457,352.00 | — | 52 | $62,001.00 | 0.17% |
Chris Meduri | Chief Medical Officer & Member of Medical Advisory Board | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$28.85M
Sells
0
$0.00
Net Sentiment
+$28.85M
Net buying
Most Active
L1 Capital Pty Ltd
2 transactions
Analysis
Insiders reported 3 buys worth $28.85M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $28.85M. L1 Capital Pty Ltd was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -22.6% | +121.4% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -22.6% over three years. Forward estimates point to Revenue at +121.4% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Anika Therapeutics, Inc.
NASDAQ:ANIK
$195.86M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Owlet, Inc.
NYSE:OWLT
$84.14M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Cassava Sciences, Inc.
SAVA
$63.77M
Atlantic International Corp.
NASDAQ:ATLN
$47.61M
Accuray Incorporated
ARAY
$40.60M
Who manages AVR?
Anteris Technologies Global Corp. (AVR) lists 4 active executives. The top listed executive is David Denis, President & Director.
Are AVR insiders buying or selling?
Recent insider activity shows net buying of $20.83M.
Explore More
Continue the stock analysis
Jump to another research area for this company.